6533b86cfe1ef96bd12c7f6e

RESEARCH PRODUCT

Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.

Joerg RahnenfuehrerMarcus SchmidtLeonie Van De SandtG HoffmannIsabel SickingKarolina EdlundAntje LebrechtMarco Johannes BattistaJan G. Hengstler

subject

Cancer ResearchMicroarraybusiness.industrymedicine.diseaseBreast cancerOncologyInterferonPlasma cell differentiationImmunologyCancer researchmedicineAdjuvant therapyAurora Kinase Askin and connective tissue diseasesbusinessTranscription factorIRF4medicine.drug

description

620 Background: The transcription factor IRF4 (interferon regulating factor 4) regulates immunoglobulin class switch recombination as well as plasma cell differentiation. We examined the prognostic significance of IRF4 mRNA expression in node-negative breast cancer. Methods: Microarray based gene-expression data for IRF4 (204562_at) were analysed in four previously published cohorts (Mainz, Rotterdam, Transbig, Yu) of node-negative breast cancer patients not treated with adjuvant therapy (n=824). A meta-analysis of previously published cohorts was performed using a random effects model. Prognostic significance of IRF4 on metastasis-free survival (MFS) was examined in the whole cohort and in different molecular subtypes: luminal A (ER+/HER2-/aurora kinase A [AURKA]low, luminal B (ER+/HER2-/AURKAhigh), basal-like (ER-/HER2-), HER2+. Independent prognostic relevance was analysed using multivariate Cox regression. Results: Higher RNA expression of IRF4 was related to better MFS in a meta-analysis of the whole...

yearjournalcountryeditionlanguage
2014-05-20Journal of Clinical Oncology
https://doi.org/10.1200/jco.2014.32.15_suppl.620